Fierce Pharma March 4, 2024
Zoey Becker

After the U.S. government last month floated its first offers for 10 drugs on Medicare as part of the negotiations process laid out in the Inflation Reduction Act (IRA), the pricing talks are now in full swing.

Every drugmaker with a product on the list has responded to the government’s Feb. 1 pricing offer with a counteroffer, the Department of Health and Human Services (HHS) said in a Monday press release.

The agency is pleased with the “good-faith, up front negotiations,” HHS Secretary Xavier Becerra said in the release. “We are committed to constructive dialogue and are glad the drug companies are coming to the table.”

The industry, for its part, has routinely voiced complaints about a “lack of transparency”...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, CMS, Govt Agencies, HHS, Insurance, Medicare, Pharma, Pharma / Biotech
GenAI and the revolution of drug development
Amgen starts two critical late-stage trials for weight loss drug MariTide
Patient Access To Cheaper Biosimilar Drugs Varies Significantly Across Pharmacy Benefit Managers
Novo Nordisk offers Wegovy for less than half the price through new direct-to-consumer pharmacy
'Not just adding another drug to your pharmacy': CAR T, explained

Share This Article